Skip to Main Content

R. Hanna, M.D., et al. Reni-cel, the first AsCas12a gene-edited cell therapy, led to hemoglobin normalization and increased fetal hemoglobin in severe sickle cell disease patients in an interim analysis of the RUBY trial. Presented at the European Hematology Association (EHA) Annual Congress. June 13-16, 2024.